Navigation Links
PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
Date:12/10/2008

- May help avoid incorrect Breast Cancer diagnosis and management

TORONTO, Dec. 10 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; PREMF.pk) today announced that it has filed a provisional patent application that describes a new simplified method of quantifying immunohistochemical staining of biomarkers. The provisional patent application was filed with the United States Patent and Trademark office. This application, based on PreMD's existing colour measurement patents and patent applications, may facilitate more accurate and cost-effective detection of biomarkers in clinical specimens.

"With the news earlier this year of breast cancer patients being incorrectly diagnosed and treated based on erroneous interpretation of immunohistochemistry tests it immediately came to our minds that our existing intellectual property and expertise in colour measurement may be useful in improving this critical situation. Today I am pleased to say that we have made significant headway in developing this concept and have submitted a provisional patent application that may be used to improve the scoring of immunohistochemical reactions resulting in more accurate and cost-effective determination of test results" said Dr. Brent Norton, CEO of PreMD. "Biomarkers, detected in human tissue samples by immunohistochemistry, are playing an increasingly important role in prognosis and treatment decisions and the new methodology has the potential to be applicable to a broad range of such biomarkers. In the lab, with our limited budget, resources and test samples, we are getting accurate positive results in 90% of cases and full agreement in over 80% of all tests. To take this program to the next step we need to find a way, in these markets, to fund the development and testing," he added.

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include PREVU* POC and PREVU* LT, both non-invasive skin cholesterol tests. The Company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions. In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


'/>"/>
SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer
2. PreMD Inc. Completes Secured Debenture Financing
3. PreMD Reports Second Quarter Results
4. PreMD Successfully Completes Project for Health & Beauty Company
5. PreMD Reports Further Positive Meetings with the FDA
6. PreMD Appeals American Stock Exchange Delisting Notification
7. PreMD Reports First Quarter Results
8. PreMD Provides Update on FDA Review
9. PreMD Reports Fiscal 2007 Results
10. PreMD Inc. Completes Debenture Financing
11. PreMD Inc. Signs Agreement with Cosmetics Conglomerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
Breaking Medicine Technology: